Advertisement


Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection

2023 ASCO Annual Meeting

Advertisement

Marie Plante, MD, of Canada’s Université Laval and the CHUQ Hotel Dieu de Québec, discusses phase III results from a study that compared radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer. The pelvic recurrence rate at 3 years in the women who underwent simple hysterectomy is not inferior to those who had radical hysterectomy. In addition, fewer surgical complications and better quality of life were observed with simple hysterectomy (LBA5511).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So the standard treatment for the management of women with early stage cervical cancer is a radical hysterectomy, which involves the removal of the uterus and cervix, of course, but also the removal of parametrial tissue in upper vagina, which is what is associated with the greater morbidity of the procedure, as well as the potential complications and quality of life impacts issues on the bowel and bladder and sexual function. What we've noticed in retrospective studies is that the rate of parametrial infiltration in women meeting low risk criteria, and that means women with lesions under two centimeters and with limited stromal invasion of the cervix based on the preoperative MRI or on the LEEP and cone, these women meeting low risk criteria, in fact, have a very low rate of parametrial extension, approximately less than 1%. And so the question is, in those women with low risk disease, perhaps there is no need to do radical surgery, and perhaps we can in fact do simple hysterectomy, which would be less radical, with less morbidity and better quality of life. So that is the concept of the SHAPE trial. We wanted to confirm this finding in a prospective, randomized study. We have entered 700 women on this study. 350 had a radical hysterectomy, 350 had a simple hysterectomy, and of course, lymph node evaluation was performed as well. And so the primary endpoint of the study was the three-year pelvic relapse rate at three years. And so the main important findings of the studies shown that they were equivalent in terms of age, stage, histology and grade. Importantly, 45% of the women were age 50 or younger, so young women. And what we found importantly is that the pelvic recurrence rate is very low in both groups, in the range of 3%, which is quite low. And the extra pelvic recurrences were also very low. The three-year pelvic recurrence, which was the main point or endpoint of the study, was 2.52% in the simple hyst and 2.17% in the radical hysterectomy, so 0.35% difference. And that meant that we reached the non-inferiority of the simple hysterectomy compared to the radical hysterectomy in the study. So that's the first important endpoint. The second element is we looked at surgical complications and we found that women who had a radical hysterectomy had three times more bladder injuries, and nearly twice the number of urethral complications. Additionally, urinary incontinence and urinary retention were statistically worse in the radical hysterectomy group, and it persisted over time, meaning that it stayed longer. The third important element of the study was the quality of life. We evaluated with the questionnaires, quality of life and sexual health, and all the domains that we analyze, which is sexual function, pain, distress, et cetera, were all in favor of the simple hysterectomy group. So in summary, for patients with low risk, early stage cervical cancer, the SHAPE trial showed non-inferiority at the three-year pelvic relapse rate. We also show a better surgical complication profile with a simple hysterectomy and better quality of life in sexual health in simple hysterectomy group. And so we believe based on the results of the SHAPE trial, that the new standard of care for the management of women with early stage, low risk disease, carefully evaluated and selected, we think the simple hysterectomy is the new standard of care, and it goes in line with surgical deescalation.

Related Videos

Leukemia

Sarah K. Tasian, MD, on Hematologic Malignancies in Children: Expert Commentary

Sarah K. Tasian, MD, of Children’s Hospital of Philadelphia, summarizes three studies presented at ASCO: genomic determinants of outcome in acute lymphoblastic leukemia (ALL), a phase III trial of inotuzumab ozogamicin for high-risk B-cell ALL, and preliminary results from the first-in-child phase II trial of bosutinib in pediatric patients with newly diagnosed chronic myeloid leukemia (Abstracts 10015, 10016, and 10017).

Lung Cancer
Genomics/Genetics

Narjust Florez, MD, and Ferdinandos Skoulidis, MD, PhD, on NSCLC: Findings on Sotorasib vs Docetaxel in the CodeBreaK 200 Trial

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Ferdinandos Skoulidis, MD, PhD, of The University of Texas MD Anderson Cancer Center, discuss results of a biomarker subgroup analysis, showing that sotorasib demonstrated consistent clinical benefit vs docetaxel in all molecularly defined subgroups of patients with pretreated KRAS G12C–mutated advanced non–small cell lung cancer (NSCLC). Although no predictive biomarkers were confirmed, novel hypothesis-generating signals were observed (Abstract 9008).

CNS Cancers

Lisa M. DeAngelis, MD, and Ingo K. Mellinghoff, MD, on Glioma: Phase III Results on Vorasidenib

Lisa M. DeAngelis, MD, and Ingo K. Mellinghoff, MD, both of Memorial Sloan Kettering Cancer Center, discuss findings from the INDIGO trial showing that the IDH1/2 inhibitor vorasidenib improves progression-free survival for patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. These data demonstrate the clinical benefit of vorasidenib in this patient population for whom chemotherapy and radiotherapy are being delayed.

Prostate Cancer

Alberto Bossi, MD, on Prostate Cancer: PEACE-1 Trial Findings on Radiotherapy Plus Systemic Treatment

Alberto Bossi, MD, of Institut Gustave Roussy, discusses phase III findings showing that combining prostate radiotherapy with systemic treatment did not improve overall survival in men with de novo metastatic castration-sensitive prostate cancer and low metastatic burden. However, best outcomes (radiographic progression–free-survival and overall survival) were observed in men receiving the standard of care plus abiraterone acetate plus prednisone with radiotherapy (Abstract LBA5000).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Karim Fizazi, MD, on Prostate Cancer: Phase III Results on Talazoparib Plus Enzalutamide as First-Line Treatment

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, of Institut Gustave Roussy, University of Paris-Saclay, discuss findings from the TALAPRO-2 study, which showed that talazoparib plus enzalutamide improved radiographic progression–free survival over standard-of-care enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer and HRR gene alterations. This regimen also delayed the time to deterioration in global health status and quality of life (Abstract 5004).

Advertisement

Advertisement




Advertisement